Assessing Patient Confidence With Biosimilars

Panelists discuss how health care professionals have varying confidence in biosimilars, driven by concerns about efficacy, safety, and interchangeability. Increased education, real-world evidence, professional engagement, transparent regulations, and comprehensive outcome data can help build trust in these alternative biologic treatments.

EP: 1.Clinical Value of Biosimilars and the Role of Interchangeability

EP: 2.The Economic Impact of Biosimilars

EP: 3.Best Practices for Employers to Maximize Uptake of Biosimilars

EP: 4.The Role of Private Label Agreements in Enhancing Access to Biosimilars

EP: 5.Key Structural and Operational Considerations for Biosimilar Adoption

EP: 6.Positioning Biosimilars in Clinical Practice

Now Viewing

EP: 7.Assessing Patient Confidence With Biosimilars

EP: 8.The Role of Different Stakeholders in Optimizing the Uptake of Biosimilars

EP: 9.The Growing Market for Biosimilars

EP: 10.Biosimilar Pricing Strategies: Understanding High-WAC and Low-WAC Models

EP: 11.The Biosimilar Shift: How PBMs Are Reshaping Formularies

EP: 12.The Road to Biosimilar Adoption: Navigating Interchangeability

EP: 13.How the IRA is Reshaping Biosimilar Adoption

EP: 14.Cost Savings Potential Associated With the Use of Biosimilars

EP: 15.Examining the Role of Interchangeability in Clinical Practice

EP: 16.Optimizing the Implementation of Biosimilars Into Formularies

EP: 17.Key Pearls for Collaborating With Manufacturers for Successful Uptake of Biosimilars

EP: 18.Working With Policy Makers to Effectively Implement Biosimilars

Video content above is prompted by the following:

• How do you view patient confidence with biosimilars so far? What can be done to increase their confidence in biosimilars?

Related Videos

Related Content

Advertisement

July 11th 2025

GLP-1 Receptor Agonists Show Promise as Adjunctive Treatment for Ovarian Cancer

Brooke McCormick

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, offering a promising adjunct to traditional treatments.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 10th 2025

SGLT2 Inhibitor Offers Kidney Protection and Reduces Heart Failure Risk After Acute Myocardial Infarction

Giuliana Grossi

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 8th 2025

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

Brooke McCormick

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

July 8th 2025

Encounter-Level Factors Drive Racial Disparities in COVID-19 Treatment Access

Brooke McCormick

Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.

Related Content

Advertisement

July 11th 2025

GLP-1 Receptor Agonists Show Promise as Adjunctive Treatment for Ovarian Cancer

Brooke McCormick

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, offering a promising adjunct to traditional treatments.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 10th 2025

SGLT2 Inhibitor Offers Kidney Protection and Reduces Heart Failure Risk After Acute Myocardial Infarction

Giuliana Grossi

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 8th 2025

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

Brooke McCormick

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

July 8th 2025

Encounter-Level Factors Drive Racial Disparities in COVID-19 Treatment Access

Brooke McCormick

Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.